Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, headquartered in The Woodlands, Texas, is advancing multiple drug candidates, including INPEFA® for heart failure, and employs a unique gene science approach based on Nobel Prize-winning technology.
Headquarters and Locations
Lexicon Pharmaceuticals is headquartered in The Woodlands, Texas. This location is situated in a forested enclave just north of Houston's Bush Intercontinental Airport, within a community known for its excellent public and private schools, shopping, dining, and performing arts venues. Additionally, Lexicon Pharmaceuticals has a location in Bridgewater, New Jersey.
INPEFA® for Heart Failure
Lexicon Pharmaceuticals is commercializing INPEFA® (sotagliflozin) for the treatment of heart failure. It is a once-daily oral tablet indicated to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors. Approved on May 26, 2023, INPEFA® is one of three SGLT inhibitors currently indicated for heart failure, demonstrating a significant reduction in the risk of cardiovascular death and heart failure rehospitalizations by greater than 50% at 30 days compared to placebo after discharge. Its approval was based on the Phase 3 cardiovascular outcomes studies, SOLOIST-WHF and SCORED.
Drug Candidates in Development
Lexicon Pharmaceuticals has advanced multiple drug candidates into late-stage clinical development. The company's drug candidate LX9211 targets Diabetic Peripheral Neuropathic Pain (DPNP) and is wholly owned. Another drug candidate, Sotagliflozin, is aimed at treating Type 1 Diabetes and Hypertrophic Cardiomyopathy (HCM) and is also wholly owned by the company. Additionally, Lexicon is evaluating a pre-clinical asset for the treatment of obesity.
Gene Science and Research
Lexicon Pharmaceuticals employs a unique approach to gene science based on Nobel Prize-winning technology. The company has systematically studied the role and function of thousands of genes, identifying more than 100 precise protein targets. This groundbreaking work has enabled the development of targeted therapies for various indications.
Collaborations and Partnerships
Lexicon Pharmaceuticals collaborates with other pharmaceutical and biotechnology companies, research institutes, and academic institutions. These partnerships enable the company to leverage external expertise and resources to advance its drug discovery and development efforts.